search
Back to results

Pre-operative Alcohol Skin Solutions in Fractured Extremities (PREPARE)

Primary Purpose

Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture

Status
Active
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
DuraPrep
ChloraPrep
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Surgical Site Infection focused on measuring Surgical Site Infection, Open Fracture, Lower Extremity Fracture, Pelvis; Fracture, DuraPrep, ChloraPrep, Peri-operative Preparation Solutions

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

The open fracture inclusion criteria are:

  1. Patients 18 years of age or older.
  2. Open fracture of the appendicular skeleton.
  3. Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.).
  4. Open fracture wound management that includes formal surgical debridement within 72 hours of their injury.
  5. Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
  6. Informed consent obtained.
  7. Patient enrolled within 3 weeks of their fracture.

The open fracture exclusion criteria are:

  1. Fracture of the hand (distal to radial carpal joint).
  2. Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication.
  3. Received previous surgical debridement or management of their fracture at a nonparticipating hospital or clinic (as applicable).
  4. Open fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist).
  5. Chronic or acute infection at or near the fracture site at the time of initial fracture surgery.
  6. Burns at the fracture site.
  7. Incarceration.
  8. Expected injury survival of less than 90 days.
  9. Terminal illness with expected survival less than 90 days.
  10. Currently enrolled in a study that does not permit co-enrollment.
  11. Unable to obtain informed consent due to language barriers.
  12. Likely problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  13. Prior or current enrollment in a PREP-IT trial.
  14. Enrolled in the PREPARE closed cohort.
  15. Excluded due to sampling strategy.

The closed fracture inclusion criteria are:

  1. Patients 18 years of age or older.
  2. Closed fracture of the lower extremity or pelvis.
  3. Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.).
  4. Fracture management requires a surgical incision (i.e., for fracture reduction or implant insertion).
  5. Will have all planned fracture care surgeries performed by a participating surgeon or delegate.
  6. Informed consent obtained.
  7. Patient enrolled within 6 weeks of their fracture.

The closed fracture exclusion criteria are:

  1. Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication.
  2. Received previous surgical management of their fracture at a non-participating hospital or clinic.
  3. Fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist).
  4. Chronic or acute infection at or near the fracture site at the time of initial fracture surgery.
  5. Burns at the fracture site.
  6. Incarceration.
  7. Expected injury survival of less than 90 days.
  8. Terminal illness with expected survival less than 90 days.
  9. Currently enrolled in a study that does not permit co-enrollment.
  10. Unable to obtain informed consent due to language barriers.
  11. Likely, problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  12. Prior or current enrollment in a PREP-IT trial.
  13. Enrolled in the PREPARE open cohort.
  14. Excluded due to sampling strategy.

Sites / Locations

  • University of California, Irvine
  • Cedars Sinai
  • Regional Medical Center of San Jose
  • Indiana University Health Methodist Hospital
  • Louisiana State University
  • University of Maryland, R Adams Cowley Shock Trauma Center
  • University of Maryland Capital Region Health
  • Massachusetts General Hospital
  • Brigham and Women's Hospital
  • University of Mississippi Medical Center
  • Bryan Health
  • Dartmouth-Hitchcock Medical Center
  • Carolinas Medical Center, Atrium Health Musculoskeletal Institute
  • Duke University Hospital
  • Wake Forest Baptist University Medical Center
  • University of Cincinnati Medical Center
  • Case Western / MetroHealth Medical Center
  • University of Pennsylvania
  • Greenville Health System
  • Sanford Health
  • San Antonio Military Medical Center
  • University of Utah
  • Inova Health System Foundation / Inova Fairfax Hospital
  • University of Wisconsin
  • Royal Columbia Hospital
  • Hamilton Health Sciences
  • McMaster University, Center for Evidence-Based Orthopaedics

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

First pre-op antiseptic skin solution

Crossover - Second pre-op antiseptic skin solution

Arm Description

The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.

Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.

Outcomes

Primary Outcome Measures

Surgical Site Infection: Superficial Incisional
Guided by the CDC's National Healthcare Safety Network reporting criteria
Surgical Site Infection: Deep Incision or Organ/Space
Guided by the CDC's National Healthcare Safety Network reporting criteria

Secondary Outcome Measures

Unplanned Fracture-Related Reoperation
Common examples include any unplanned fracture-related surgery that is associated with an infection at the operative site or contiguous to it, a wound-healing problem, or a fracture delayed union or non-union.

Full Information

First Posted
April 30, 2018
Last Updated
May 5, 2023
Sponsor
University of Maryland, Baltimore
Collaborators
McMaster University, Patient-Centered Outcomes Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03523962
Brief Title
Pre-operative Alcohol Skin Solutions in Fractured Extremities
Acronym
PREPARE
Official Title
PREPARE: A Pragmatic Randomized Trial Evaluating Pre-operative Alcohol Skin Solutions in FRactured Extremites
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 21, 2018 (Actual)
Primary Completion Date
March 15, 2023 (Actual)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore
Collaborators
McMaster University, Patient-Centered Outcomes Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The prevention of infection is an important goal influencing peri-operative care of extremity fracture patients. Standard practice in the operative management of extremity fractures includes sterile technique and pre-operative skin preparation with an antiseptic solution. The available solutions kill bacteria and decrease the quantity of native skin flora, thereby decreasing surgical site infection (SSI). While there is extensive guidance on specific procedures for prophylactic antibiotic use and standards for sterile technique, the evidence regarding the choice of antiseptic skin preparation solution is very limited for extremity fracture surgery.
Detailed Description
More than one million Americans suffer an extremity fracture (broken bone in the arm, leg, or pelvis) that requires surgery each year. Approximately 5% (or 50,000) of surgical fracture patients develop a surgical site infection (SSI), which is twice the rate among most surgical patients and nearly five times the rate among patients undergoing elective orthopaedic surgeries (e.g. joint replacement). Patients who develop a SSI after their fracture fixation surgery experience a long and difficult treatment pathway. Researchers have identified that when a fracture patient experiences a SSI, they typically undergo at least two additional surgeries to control the infection, spend a median of 14 additional days in the hospital, and have significantly lower health related quality of life (HRQL). Similarly, results from the recently completed Fluid Lavage of Open Wounds (FLOW) trial confirmed that patients who had a SSI, or another complication, that required an additional surgery reported significantly lower physical and mental HRQL in the 12 months following their fracture compared to patients who did not experience a SSI. In the most severe cases, when a SSI cannot be controlled, a limb amputation becomes necessary. Open fractures, closed lower extremity fractures, and pelvic fractures represent some of the most severe musculoskeletal injuries. Due to their high-energy mechanisms, these fractures are often accompanied by soft-tissue injuries that contribute to unacceptably poor outcomes. The FLOW trial of 2,447 open fracture patients reported a 13.2% incidence of open fracture-related reoperations; Closed fractures of the lower extremity are also at high risk of complications, particularly when compared to closed upper extremity fractures. For example, the rate of SSI in closed tibial plateau and plafond fractures range from 5.6 - 11.9%, although some cohort studies have reported infection rates as high as 25.0%. This is contrast with SSI rates of <5% for common upper extremity fractures like humeral shaft, forearm, or distal radius fractures. This is further illustrated in a series of 214 deep orthopaedic fracture infections, in which 58% occurred in the tibia and ankle, and only 10% occurred anywhere in the upper extremity. Finally, pelvic fractures are associated with some of the most challenging SSIs to treat among closed fractures because of their propensity to gram negative organisms and limitations in reconstruction options post-infection. Ultimately, infectious complications in these fracture populations lead to prolonged morbidity, loss of function, and potential limb loss.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture, Closed Lower Extremity Fracture, Pelvic Fracture
Keywords
Surgical Site Infection, Open Fracture, Lower Extremity Fracture, Pelvis; Fracture, DuraPrep, ChloraPrep, Peri-operative Preparation Solutions

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Model Description
Treatment allocation will be determined using a cluster-randomized crossover trial design. The open and closed fracture populations will be treated with the same allocated solution at all times during the trial. The order of treatment allocation for each orthopaedic practice will be randomly assigned using a computer-generated randomization table. Each site will start with the initially allocated study solution and eventually crossover to the other solution for their second recruitment period. This process of alternating treatments will repeat approximately every 2 months as dictated by the initial randomization.
Masking
Outcomes Assessor
Masking Description
The orthopaedic team (including the study coordinators) cannot be blinded to the treatment allocation as the antiseptic solutions are visually distinguishable and these individuals need to lead the implementation of the cluster-crossover protocol at their clinical site. The Adjudication Committee Members and data analysts will be blinded to the study treatment. All interpretation of study results will initially be done in a blinded manner by developing two interpretations of the results. One interpretation will assume treatment A is iodine povacrylex, the other interpretation will assume it is CHG. Once the data interpretations for each assumption are finalized, the data will be unblinded and the correct interpretation will be accepted.
Allocation
Randomized
Enrollment
8000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
First pre-op antiseptic skin solution
Arm Type
Experimental
Arm Description
The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
Arm Title
Crossover - Second pre-op antiseptic skin solution
Arm Type
Experimental
Arm Description
Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
Intervention Type
Drug
Intervention Name(s)
DuraPrep
Intervention Description
The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.
Intervention Type
Drug
Intervention Name(s)
ChloraPrep
Intervention Description
The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.
Primary Outcome Measure Information:
Title
Surgical Site Infection: Superficial Incisional
Description
Guided by the CDC's National Healthcare Safety Network reporting criteria
Time Frame
Within 30 days of the patient's last planned fracture management surgery
Title
Surgical Site Infection: Deep Incision or Organ/Space
Description
Guided by the CDC's National Healthcare Safety Network reporting criteria
Time Frame
Within 90 days of the patient's last planned fracture management surgery
Secondary Outcome Measure Information:
Title
Unplanned Fracture-Related Reoperation
Description
Common examples include any unplanned fracture-related surgery that is associated with an infection at the operative site or contiguous to it, a wound-healing problem, or a fracture delayed union or non-union.
Time Frame
Within 12 months of the patient's last planned operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
The open fracture inclusion criteria are: Patients 18 years of age or older. Open fracture of the appendicular skeleton. Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.). Open fracture wound management that includes formal surgical debridement within 72 hours of their injury. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Informed consent obtained. Patient enrolled within 3 weeks of their fracture. The open fracture exclusion criteria are: Fracture of the hand (distal to radial carpal joint). Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication. Received previous surgical debridement or management of their fracture at a nonparticipating hospital or clinic (as applicable). Open fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist). Chronic or acute infection at or near the fracture site at the time of initial fracture surgery. Burns at the fracture site. Incarceration. Expected injury survival of less than 90 days. Terminal illness with expected survival less than 90 days. Currently enrolled in a study that does not permit co-enrollment. Unable to obtain informed consent due to language barriers. Likely problems, in the judgment of study personnel, with maintaining follow-up with the patient. Prior or current enrollment in a PREP-IT trial. Enrolled in the PREPARE closed cohort. Excluded due to sampling strategy. The closed fracture inclusion criteria are: Patients 18 years of age or older. Closed fracture of the lower extremity or pelvis. Received or will receive definitive fracture treatment with a surgical implant(s) (i.e., internal fixation, external fixation, joint prosthesis, etc.). Fracture management requires a surgical incision (i.e., for fracture reduction or implant insertion). Will have all planned fracture care surgeries performed by a participating surgeon or delegate. Informed consent obtained. Patient enrolled within 6 weeks of their fracture. The closed fracture exclusion criteria are: Patients who did not or will not receive the allocated pre-operative surgical preparation solution due to a medical contraindication. Received previous surgical management of their fracture at a non-participating hospital or clinic. Fracture managed outside of the participating orthopaedic service (e.g., foot fracture managed by podiatrist). Chronic or acute infection at or near the fracture site at the time of initial fracture surgery. Burns at the fracture site. Incarceration. Expected injury survival of less than 90 days. Terminal illness with expected survival less than 90 days. Currently enrolled in a study that does not permit co-enrollment. Unable to obtain informed consent due to language barriers. Likely, problems, in the judgment of study personnel, with maintaining follow-up with the patient. Prior or current enrollment in a PREP-IT trial. Enrolled in the PREPARE open cohort. Excluded due to sampling strategy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard Slobogean, MD
Organizational Affiliation
University of Maryland Shock Trauma Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sheila Sprague, PhD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mohit Bhandari, MD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Irvine
City
Irvine
State/Province
California
ZIP/Postal Code
92697
Country
United States
Facility Name
Cedars Sinai
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Regional Medical Center of San Jose
City
San Jose
State/Province
California
ZIP/Postal Code
95126
Country
United States
Facility Name
Indiana University Health Methodist Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Louisiana State University
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70803
Country
United States
Facility Name
University of Maryland, R Adams Cowley Shock Trauma Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
University of Maryland Capital Region Health
City
Cheverly
State/Province
Maryland
ZIP/Postal Code
20785
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Facility Name
Bryan Health
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Dartmouth-Hitchcock Medical Center
City
Hanover
State/Province
New Hampshire
ZIP/Postal Code
03755
Country
United States
Facility Name
Carolinas Medical Center, Atrium Health Musculoskeletal Institute
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
Duke University Hospital
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27708
Country
United States
Facility Name
Wake Forest Baptist University Medical Center
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
University of Cincinnati Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Case Western / MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Greenville Health System
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
Sanford Health
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57117
Country
United States
Facility Name
San Antonio Military Medical Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78234
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States
Facility Name
Inova Health System Foundation / Inova Fairfax Hospital
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53715
Country
United States
Facility Name
Royal Columbia Hospital
City
New Westminster
State/Province
British Columbia
Country
Canada
Facility Name
Hamilton Health Sciences
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
McMaster University, Center for Evidence-Based Orthopaedics
City
Hamilton
State/Province
Ontario
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32787892
Citation
Sprague S, Scott T, Dodds S, Pogorzelski D, McKay P, Harris AD, Wood A, Thabane L, Bhandari M, Mehta S, Gaski G, Boulton C, Marcano-Fernandez F, Guerra-Farfan E, Hebden J, O'Hara LM, Slobogean GP; PREP-IT Investigators. Cluster identification, selection, and description in cluster randomized crossover trials: the PREP-IT trials. Trials. 2020 Aug 12;21(1):712. doi: 10.1186/s13063-020-04611-9. Erratum In: Trials. 2020 Sep 30;21(1):821.
Results Reference
derived
PubMed Identifier
32259266
Citation
Program of Randomized Trials to Evaluate Pre-operative Antiseptic Skin Solutions in Orthopaedic Trauma (PREP-IT) Investigators; Slobogean GP, Sprague S, Wells J, Bhandari M, Rojas A, Garibaldi A, Wood A, Howe A, Harris AD, Petrisor BA, Mullins DC, Pogorzelski D, Marvel D, Heels-Ansdell D, Mossuto F, Grissom F, Del Fabbro G, Guyatt GH, Della Rocca GJ, Demyanovich HK, Gitajn IL, Palmer J, D'Alleyrand JC, Friedrich J, Rivera J, Hebden J, Rudnicki J, Fowler J, Jeray KJ, Thabane L, Marchand L, O'Hara LM, Joshi MG, Talbot M, Camara M, Szasz OP, O'Hara NN, McKay P, Devereaux PJ, O'Toole RV, Zura R, Morshed S, Dodds S, Li S, Tanner SL, Scott T, Nguyen U. Effectiveness of Iodophor vs Chlorhexidine Solutions for Surgical Site Infections and Unplanned Reoperations for Patients Who Underwent Fracture Repair: The PREP-IT Master Protocol. JAMA Netw Open. 2020 Apr 1;3(4):e202215. doi: 10.1001/jamanetworkopen.2020.2215. Erratum In: JAMA Netw Open. 2020 Sep 1;3(9):e2021571. JAMA Netw Open. 2021 Jun 1;4(6):e2117240.
Results Reference
derived

Learn more about this trial

Pre-operative Alcohol Skin Solutions in Fractured Extremities

We'll reach out to this number within 24 hrs